Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA registry

Haematologica. 2024 Aug 1;109(8):2693-2700. doi: 10.3324/haematol.2023.284678.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • COVID-19 Drug Treatment*
  • COVID-19* / complications
  • COVID-19* / mortality
  • Dexamethasone* / therapeutic use
  • Female
  • Hematologic Neoplasms* / drug therapy
  • Hematologic Neoplasms* / mortality
  • Humans
  • Male
  • Middle Aged
  • Registries*
  • SARS-CoV-2* / isolation & purification

Substances

  • Dexamethasone